IN DEPTHRunning low on comparators: drug shortages in oncology clinical trialsACT EU state of play: EMA’s headway to transform clinical trialsCMO Moves: Regulatory catalysts for drug manufacturing-December2023 OutlookHumira biosimilars set the stage for long-awaited 2023 US launchesAfter much buzz, the entry of Humira biosimilars is being seen as a major cost-cutting opportunity, but market penetration will not be instantR&DExpanding ketamine’s horizons for rare neurological disordersR&DThe “Medical Bypass”: New drugs to strike obesityRunning low on comparators: drug shortages in oncology clinical trialsACT EU state of play: EMA’s headway to transform clinical trialsCMO Moves: Regulatory catalysts for drug manufacturing-December02/23/2024 23:26:13
Running low on comparators: drug shortages in oncology clinical trials
ACT EU state of play: EMA’s headway to transform clinical trials
CMO Moves: Regulatory catalysts for drug manufacturing-December